Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

Potential inhibitors of SARS-CoV-2 identified

Potential inhibitors of SARS-CoV-2 identified

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Small molecule drugs binding Mac1 domain of SARS-CoV-2

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers identify new pathway as biological target for colon cancer

Researchers identify new pathway as biological target for colon cancer

Kobe scientists develop mathematical model to predict cancer drug side effects

Kobe scientists develop mathematical model to predict cancer drug side effects

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

New trial shows improved survival for patients with advanced colorectal BRAF-mutant cancer

Study: Three-drug combination improves overall survival in patients with mCRC

Study: Three-drug combination improves overall survival in patients with mCRC

New drug combinations and dosing schedules improve outlook in advanced colon cancer

New drug combinations and dosing schedules improve outlook in advanced colon cancer

UA scientists aim to identify drug targets for rare pediatric cancer

UA scientists aim to identify drug targets for rare pediatric cancer

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients